| Literature DB >> 31733443 |
Fausto Petrelli1, Agostina De Stefani2, Francesca Trevisan2, Chiara Parati3, Alessandro Inno4, Barbara Merelli5, Michele Ghidini6, Lorenza Bruschieri2, Elisabetta Vitali2, Mary Cabiddu3, Karen Borgonovo3, Mara Ghilardi3, Sandro Barni3, Antonio Ghidini7.
Abstract
Radiotherapy (RT) represents a mainstay in the treatment of brain metastases (BMs) from solid tumors. Immunotherapy (IT) has improved survival of metastatic cancer patients across many tumor types. The combination of RT and IT for the treatment of BMs has a strong rationale, but data on efficacy and safety of this combination is still limited. A systematic search of PubMed, the Cochrane Central Register of Controlled Trials, and EMBASE was conducted. 33 studies were included for a total of 1520 patients, most of them with melanoma (87%). Median pooled OS was 15.9 months (95%CI 13.9-18.1). One- and 2-year OS rates were 55.2% (95% CI 49.3-60.9) and 35.7% (95% CI 30.4-41.3), respectively. Addition of IT to RT was associated with improved OS (HR = 0.54, 95%CI 0.44-0.67; P < 0.001). For patients with BMs from solid tumors, addition of concurrent IT to brain RT is able to increase survival and provide long term control.Entities:
Keywords: Brain metastases; Immunotherapy; Meta-analysis; Radiotherapy; Survival
Year: 2019 PMID： 31733443 DOI： 10.1016/j.critrevonc.2019.102830
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312